Patterns of first-line targeted therapy utilization and adherence among older adults diagnosed with metastatic renal cell carcinoma

• Published in: Journal of geriatric oncology 2022-04, Vol.13 (3), p.325-333
• Main Authors: Hicks, Blánaid M., Chun, Danielle S., Peacock Hinton, Sharon, Hsu, Christine D., Tan, Hung-Jui, Lund, Jennifer L.
• Format: Article
• Language: English
• Subjects: Adherence; Aged; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - pathology; Female; Humans; Kidney Neoplasms - pathology; Male; Metastatic; Pazopanib; Renal cell carcinoma; Retrospective Studies; Sunitinib; Targeted therapy; United States
• ISSN: 1879-4068; 1879-4076
• DOI: 10.1016/j.jgo.2021.11.006

Despite the rapid approval of targeted therapies for metastatic renal cell carcinoma (mRCC) evidence on real world treatment patterns remains limited. This study evaluated patterns of first-line targeted therapy utilization and adherence in older adults, a population with a high burden of RCC. 2093 patients aged ≥66 years with a primary diagnosis of mRCC were identified from United States (US)-based cancer registry and administrative claims data (2007–2015). We included only patients with de novo disease. We assessed the initiation of first-line targeted therapy within four months of diagnosis and persistence and adherence to targeted therapy, using the proportion of days covered (PDC). Multivariable logistic regression yielded adjusted odds ratios (ORs) and 95% confidence intervals (CIs) to describe characteristics associated with targeted therapy versus no targeted therapy initiation and for high (≥80% PDC) versus low adherence. 28.8% of patients received first-line targeted therapy within four months of diagnosis, with the proportion of patients receiving targeted therapy increasing over time. Older age (one-year increment OR:0.95 95%CI 0.93, 0.97), high comorbidity burden (OR:0.65 95%CI0.46, 0.93) and clear cell histology (OR:1.54 95%CI 1.19, 2.00) were associated with targeted therapy initiation. 48.2% of patients exhibited a high PDC to oral targeted therapy at 120 days, which was attenuated with inclusion of patients who died during the time period (34.2% PDC ≥80%). Increasing age, high comorbidity burden and non-clear cell histology were associated with decreased targeted therapy initiation among patients with de novo mRCC. Our findings suggest adherence to oral therapies was low; future research exploring the mechanisms and impact of low adherence in this older patient population is warranted.